Tünde Kristóf

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

K Gecse, Barbara D. Lovász, Klaudia Farkas et al. · Journal of Crohn s and Colitis · 2015 · 183 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +12

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

Silvio Danese, Jean‐Frédéric Colombel, Milan Lukáš et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 93 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 93 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

Lóránt Gönczi, K Gecse, Zsuzsanna Végh et al. · Inflammatory Bowel Diseases · 2017 · 57 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16